XOMA (XOMA Royalty) Beta: 0.5054 (As of Jun. 24, 2026)


XOMA XOMA Royalty Corp XOMA
45 GF Score
Price $42.18
GF Value $18.84
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is XOMA Royalty Beta?

XOMA Royalty XOMA +0.48% 45 Beta is 0.5054 as of Jun. 24, 2026. GuruFocus rates XOMA with a GF Score™ of 45/100 and a GF Value™ of $18.84 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), XOMA Royalty's Beta is 0.5054.


XOMA Royalty  (NAS:XOMA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


XOMA Royalty Beta Related Terms


XOMA Royalty Beta Historical Data

* Premium members only.

The historical data trend for XOMA Royalty's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty Beta Chart

XOMA Royalty Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 1.12 0.73 0.68 0.41

XOMA Royalty Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.72 0.56 0.41 -0.06

XOMA vs EDIT, FDMT, KYTX: Beta Comparison

For the Biotechnology subindustry, XOMA Royalty's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Beta distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Beta falls into.


XOMA
45GF Score
XOMA Royalty Corp XOMA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XOMA Royalty Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5054 mean?
XOMA Royalty (XOMA) has a Beta of 0.5054 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for XOMA Royalty and its competitors.
Is XOMA Royalty's Beta too high?
XOMA Royalty's current Beta is 0.5054. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's Beta compare to EDIT and FDMT?
XOMA Royalty's Beta of 0.5054 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for XOMA Royalty and its competitors. XOMA Royalty's current Beta is 0.5054. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.84, compared to a current price of $42.18 — trading 123.9% above its estimated fair value. The current Beta is 0.5054. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current Beta is 0.5054 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XOMA Royalty (XOMA) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $42.18 is trading 123.9% above its estimated GF Value™ of $18.84. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for XOMA:

  • Beta: 0.5054
  • GF Value™: $18.84 vs. price of $42.18 (123.9% above fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score

Get the complete analysis for XOMA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.18
Price
$18.84
GF Value